Osteonecrosis of the jaws and bisphosphonatesreport of fifteen cases: therapeutic recommendations

  1. Ignacio Heras Rincón 1
  2. Ignacio Zubillaga 1
  3. M. Castrillo Tambay 2
  4. J.J. Montalvo Moreno 1
  1. 1 12 de octubre University Hospital. Madrid
  2. 2 General Hospital. Ciudad Real
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Year of publication: 2007

Volume: 12

Issue: 4

Pages: 1

Type: Article

More publications in: Medicina oral, patología oral y cirugía bucal. Ed. inglesa


Cited by

  • Scopus Cited by: 13 (02-09-2023)

SCImago Journal Rank

  • Year 2007
  • SJR Journal Impact: 0.43
  • Best Quartile: Q2
  • Area: Otorhinolaryngology Quartile: Q2 Rank in area: 44/103
  • Area: Medicine (miscellaneous) Quartile: Q2 Rank in area: 1096/2912
  • Area: Surgery Quartile: Q2 Rank in area: 134/360
  • Area: Dentistry (miscellaneous) Quartile: Q2 Rank in area: 35/99


Recently there have been reports of osteonecrosis of the jaw (ONJ) in patients with chronic therapy with bisphosphonates (Bps). So far three drugs have been linked: Pamidronate of disodium, Zoledronic acid and Alendronate of sodium. It is due to a non detected side effect in clinical trials before commercialization, and reverberates significantly in the quality of life of these patients. Most of the cases are seen in oncology patients that have received long term concurrent antineoplasic therapy and were treated sporadically with steroids, together with Bps endovenous, for treatment of cancer and its symptoms. Among these cases we find the reported by R.E. Marx (1), S.L. Ruggiero (2) and J. V. Bagán (3). In this report fifteen cases diagnosed, treated and followed up at the author´s surgery department are presented and some suggestions are given in order to reduce the incidence in patients with cancer who are going to receive Bps, as well as in patients with established ONJ being treated with these drugs who may need a surgical intervention.